🇺🇸 FDA
Patent

US 10308698

Therapeutic targeting of SET1B/compass pathway for treating cancers

granted A61KA61K38/2264

Quick answer

US patent 10308698 (Therapeutic targeting of SET1B/compass pathway for treating cancers) held by Northwestern University expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Northwestern University
Grant date
Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K38/2264